---
schema_version: "secwatch.filing_event.v1"
accession: "0001810560-25-000006"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2025-09-09T23:59:59+00:00"
generated_at: "2026-05-17T07:20:20.623952+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences PRIME Phase 1b CKD study hits endpoints; Gemini reduces inflammation in high-background patients

## Summary
- Gemini met primary safety endpoint; well-tolerated at target dose with only mild Grade I events.
- In patients with high background inflammation (≈50%), Gemini significantly reduced IL-1β, TNF-α, IL-6, IL-10, IL-1RA vs placebo (p<0.01) through 7 days.
- Gemini restored normal cellular response to LPS/HMGB1 stimuli in high-background PBMCs, reversing immunoparalysis (IL-1β p<0.0001).
- Company scheduled End of Phase 1 meeting with FDA later in 2025 to discuss advancement.
- 40 patients enrolled across 5 dose cohorts in 3 US clinics; data webcast on Sept 10, 2025 at 8:30 AM ET.

## SEC filing metadata
- accession: 0001810560-25-000006
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2025-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000181056025000006/0001810560-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000181056025000006/revb-20250909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001810560-25-000006
- JSON: https://secwatch.observer/filing/0001810560-25-000006.json
- Plain text: https://secwatch.observer/filing/0001810560-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.